par Ades, F;Senterre, Christelle
;Zardavas, Dimitros
;de Azambuja, Evandro
;Popescu, Razvan;Parent, Florence
;Piccart-Gebhart, Martine 
Référence European journal of cancer, 50, 18, page (3089-3097)
Publication Publié, 2014-12





Référence European journal of cancer, 50, 18, page (3089-3097)
Publication Publié, 2014-12
Article révisé par les pairs
Résumé : | The European Union (EU) has adopted a common procedure for granting marketing authorisation for cancer drugs. Nevertheless, pricing and reimbursement decisions are a competency of EU national governments, and their policies are diverse. We aimed to evaluate the time for trastuzumab reimbursement approval and its association to health expenditure, to health policy performance, to the availability of cost-effectiveness studies and to breast cancer outcome. |